---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-013927"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:24:02.462928+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023

## Summary
- Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
- Cash, cash equivalents and marketable securities $167.4M as of June 30, 2023, funding operations into Q2 2025.
- OPERA-01 pivotal Phase 3 trial of palazestrant (OP-1250) monotherapy to enroll first patient in Q4 2023.
- Palazestrant Phase 2 monotherapy data as oral presentation at ESMO Congress October 22, 2023.
- Interim Phase 1b/2 combination data with CDK4/6 inhibitors to be presented in Q4 2023.

## SEC filing metadata
- accession: 0001558370-23-013927
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/0001558370-23-013927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/olma-20230808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-013927
- JSON: https://secwatch.observer/filing/0001558370-23-013927.json
- Plain text: https://secwatch.observer/filing/0001558370-23-013927.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/0001558370-23-013927-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.